54P Real-world pCR outcomes and predictive performance of the HER2DX pCR likelihood score in early-stage HER2-positive breast cancer: A multicenter prospective subanalysis

Key Points

This study aims to define the molecular landscape in HER2-positive breast cancer based on the timing of recurrence and its implications for overall survival.
Analyzed plasma ctDNA of patients with mTNBC in the STING trial (NCT04932525) based on recurrence timing.
Classified recurrences into early, late, and de novo, with survival assessment through Kaplan-Meier and log-rank tests.
Used chi-square/Fisher's exact and Kruskal-Wallis tests to compare alterations among groups.
Early recurrence occurred in 38% of patients with increased TP53 alterations (86%).
Median overall survival for early relapses was 20.4 months, significantly shorter than late (41 months) and de novo (29 months).
Recurrence 12 months post-chemotherapy improved overall survival, while high tumor fraction worsened outcomes.

Analyzes pCR scores in early-stage HER2-positive breast cancer, suggesting outcome disparities based on timing of recurrence.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Saez et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share